BioAdaptives, Inc. (OTC: BDPT) has detailed the scientific strategy behind its Xcellara cellular wellness platform ahead of the planned August 1 commercial launch of XcellaraHeart. The platform combines a stem/progenitor cell mobilization base with tissue-specific ingredients designed to support the body’s natural signaling pathways and direct those cells to targeted areas. The base is supported by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells.
XcellaraHeart, the platform's first commercial application, pairs the Xcellara base with Tanshinone IIA, a compound derived from Danshen studied for its role in cardiovascular SDF-1α/CXCR4 signaling. This signaling pathway is crucial for directing stem cells to damaged heart tissue. The company plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness, and metabolic resilience, using the same supply-and-direction development model.
BioAdaptives' flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks, with zero adverse effects on more than twenty blood parameters. The complete scientific evidence dossier for XcellaraHeart will be available at products.xcellara.com/science, separating demonstrated human clinical research from published studies on Tanshinone IIA and the company's product-development rationale.
The announcement underscores BioAdaptives' commitment to evidence-based supplements that leverage the body's own regenerative mechanisms. By targeting specific tissues with additional signaling ingredients, the Xcellara platform aims to address a range of health concerns beyond cardiovascular support. This approach could represent a significant advancement in the dietary supplement industry, where products often lack rigorous clinical validation.
Investors and consumers will be watching closely as XcellaraHeart hits the market, given the potential implications for heart health and the broader applicability of the platform. For more information about the company and its products, visit www.bioadaptives.com.
